Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Per, Hydbring"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/6b0b43656e8345c7b4567c76307cefb1
Autor:
Bo Franzén, Kristina Viktorsson, Caroline Kamali, Eva Darai‐Ramqvist, Vitali Grozman, Vasiliki Arapi, Petra Hååg, Vitaliy O. Kaminskyy, Per Hydbring, Lena Kanter, Sven Nyrén, Simon Ekman, Luigi De Petris, Rolf Lewensohn
Publikováno v:
Molecular Oncology, Vol 15, Iss 11, Pp 2941-2957 (2021)
Biomarker signatures identified through minimally invasive procedures already at diagnosis of non‐small‐cell lung cancer (NSCLC) could help to guide treatment with immune checkpoint inhibitors (ICI). Here, we performed multiplex profiling of immu
Externí odkaz:
https://doaj.org/article/9e0829fc3242405c83f4c08c0562067b
Autor:
Liqin Cheng, Dominika Kaźmierczak, Johanna Norenhag, Marica Hamsten, Emma Fransson, Ina Schuppe-Koistinen, Matts Olovsson, Lars Engstrand, Per Hydbring, Juan Du
Publikováno v:
mSystems, Vol 6, Iss 3 (2021)
Vaginal microbiota is correlated with women’s health, where a non- Lactobacillus
Externí odkaz:
https://doaj.org/article/6423db6f9e6f479b9503a3df3e94bf4f
Autor:
Per Hydbring
Publikováno v:
Translational Lung Cancer Research. 12:405-407
Autor:
Boxi Zhang, Adi Zheng, Per Hydbring, Gorbatchev Ambroise, Amanda Tomie Ouchida, Michel Goiny, Helin Vakifahmetoglu-Norberg, Erik Norberg
Publikováno v:
Cell Reports, Vol 19, Iss 11, Pp 2289-2303 (2017)
Molecular signatures are emerging determinants of choice of therapy for lung adenocarcinomas. An evolving therapeutic approach includes targeting metabolic dependencies in cancers. Here, using an integrative approach, we have dissected the metabolic
Externí odkaz:
https://doaj.org/article/1402fe92a00d4c4d88f4898e567a3e40
Autor:
Lars-Gunnar Larsson, John Inge Johnsen, Sven Nelander, Laura Baranello, Sören Lehmann, Per Hydbring, Loay Mahmoud, Sheryl Y. Lim, Linnéa Schmidt, Vasiliki Verschut, Thale Kristin Olsen, Cecilia Dyberg, Donald P. Cameron, Cecilia Krona, Marcela Franco, Mohammad Alzrigat, Malin Wickström, Fan Zhang, Wesam Bazzar, Karin Fawkner, Qinzi Yan, Alina Castell
Deregulated expression of MYC family oncogenes occurs frequently in human cancer and is often associated with aggressive disease and poor prognosis. While MYC is a highly warranted target, it has been considered “undruggable,” and no specific ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23a431701aaf0ab30ac5e1fe7ec1b18f
https://doi.org/10.1158/2767-9764.c.6550598
https://doi.org/10.1158/2767-9764.c.6550598
Complex glandular pattern as an independent predictor of survival probability in lung adenocarcinoma
Autor:
Per, Hydbring
Publikováno v:
Translational Lung Cancer Research. 11:1739-1741
Autor:
Ekman, Georgios Tsakonas, Andreas Koulouris, Dominika Kazmierczak, Johan Botling, Cristian Ortiz-Villalon, Helena Nord, Magnus Lindskog, Martin Sandelin, Patrick Micke, Per Hydbring, Simon
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 1; Pages: 193
Distant spreading of tumor cells to the central nervous system in non-small cell lung cancer (NSCLC) occurs frequently and poses major clinical issues due to limited treatment options. RNAs displaying differential expression in brain metastasis versu
Autor:
Georgios, Tsakonas, Andreas, Koulouris, Dominika, Kazmierczak, Johan, Botling, Cristian, Ortiz-Villalon, Helena, Nord, Magnus, Lindskog, Martin, Sandelin, Patrick, Micke, Per, Hydbring, Simon, Ekman
Publikováno v:
International journal of molecular sciences. 24(1)
Distant spreading of tumor cells to the central nervous system in non-small cell lung cancer (NSCLC) occurs frequently and poses major clinical issues due to limited treatment options. RNAs displaying differential expression in brain metastasis versu
Autor:
Ekman, Zeinab Kosibaty, Odd Terje Brustugun, Inger Johanne Zwicky Eide, Georgios Tsakonas, Oscar Grundberg, Luigi De Petris, Marc McGowan, Per Hydbring, Simon
Publikováno v:
Cancers; Volume 14; Issue 14; Pages: 3430
Treatment with the tyrosine kinase inhibitor (TKI) osimertinib is the standard of care for non-small cell lung cancer (NSCLC) patients with activating mutations in the epidermal growth factor receptor (EGFR). Osimertinib is also used in T790M-positiv